Another Kid on the Block: Long-acting FGF21 Analogue to Treat Dyslipidemia and Fatty Liver

被引：5
|
作者：
Yang, Ranyao [1 ,2 ]
Xu, Aimin [1 ,2 ,3 ]
Kharitonenkov, Alexei [4 ]
机构：
[1] Univ Hong Kong, State Key Lab Pharmaceut Biotechnol, Pokfulam, Hong Kong 999077, Peoples R China
[2] Univ Hong Kong, Dept Med, Pokfulam, Hong Kong 999077, Peoples R China
[3] Univ Hong Kong, Dept Pharmacol & Pharm, Pokfulam, L8-39,Lab Block,21 Sassoon Rd, Hong Kong 999077, Peoples R China
[4] AK Biotechnol LLC, 430 Amador Ln, W Palm Beach, FL 33401 USA
来源：
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | 2022年 / 107卷 / 01期
关键词：
fibroblast growth factor 21 (FGF21); hypertriglyceridemia; obesity; nonalcoholic fatty liver diseases (NAFLD); metabolism;
D O I：
10.1210/clinem/dgab686
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E417 / E419
页数：3
相关论文
共 50 条
  • [1] Albumin-fused long-acting FGF21 analogue for the treatment of non-alcoholic fatty liver disease
    Chikamatsu, Mayuko
    Watanabe, Hiroshi
    Shintani, Yuhi
    Murata, Ryota
    Miyahisa, Masako
    Nishinoiri, Ayano
    Imafuku, Tadashi
    Takano, Mei
    Arimura, Nanaka
    Yamada, Kohichi
    Kamimura, Miya
    Mukai, Baki
    Satoh, Takao
    Maeda, Hitoshi
    Maruyama, Toru
    JOURNAL OF CONTROLLED RELEASE, 2023, 355 : 42 - 53
  • [2] Development of Zalfermin, a Long-Acting Proteolytically Stabilized FGF21 Analog
    Sass-Orum, Kristian
    Tagmose, Tina Moller
    Olsen, Jorgen
    Sjolander, Annika
    Wahlund, Per-Olof
    Han, Dan
    Vegge, Andreas
    Reedtz-Runge, Steffen
    Wang, Zhe
    Gao, Xiang
    Wieczorek, Birgit
    Lamberth, Kasper
    Lykkegaard, Kirsten
    Nielsen, Peter Kresten
    Thogersen, Henning
    Yu, Mingrui
    Wang, Jianhua
    Drustrup, Jorn
    Zhang, Xujia
    Garibay, Patrick
    Hansen, Kristian
    Hansen, Ann Maria Kruse
    Andersen, Birgitte
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (14) : 11769 - 11788
  • [3] Fatty liver and FGF21 physiology
    Maratos-Flier, Eleftheria
    EXPERIMENTAL CELL RESEARCH, 2017, 360 (01) : 2 - 5
  • [4] A novel long-acting FGF21 analogue significantly improves liver steatosis and halters progression of fibrosis in pre-clinical models of NASH
    Henriksson, Emma
    Norlin, Jenny
    Galsgaard, Elisabeth D.
    Kirk, Rikke K.
    Rakipovski, Gunaj
    Andersen, Birgitte
    HEPATOLOGY, 2017, 66 : 1061A - 1061A
  • [5] Sustained reduction of triglyceride and LDL cholesterol from single administration of the novel long-acting FGF21 analogue 0499
    Dahl, Kirsten
    Friedrichsen, Martin
    Ribel-Madsen, Rasmus
    Hansen, Jakob Schioler
    Clausen, Jesper
    Axelsen, Mads
    Palle, Mads Sundby
    Key, Cassandra
    Murakami, Harumi
    Andersen, Birgitte
    JOURNAL OF HEPATOLOGY, 2022, 77 : S720 - S720
  • [6] Long-Acting FGF21 Inhibits Retinal Vascular Leakage in In Vivo and In Vitro Models
    Tomita, Yohei
    Fu, Zhongjie
    Wang, Zhongxiao
    Cakir, Bertan
    Cho, Steve S.
    Britton, William
    Sun, Ye
    Hellstrom, Ann
    Talukdar, Saswata
    Smith, Lois E. H.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (04)
  • [7] Enhanced bioactivity and stability of a long-acting FGF21: A novel variant for the treatment of NASH
    Ji, Yue
    Lu, Qingzhou
    Duan, Yiliang
    Chen, Xuan
    Zhang, Yuxi
    Yao, Wenbing
    Yin, Jun
    Gao, Xiangdong
    BIOCHIMIE, 2024, 225 : 26 - 39
  • [8] Long-acting FGF21 inhibits retinal vascular leakage in vivo and in vitro model
    Tomita, Yohei
    Fu, Zhongjie
    Cakir, Bertan
    Sun, Ye
    Wang, Zongxiao
    Liu, Chi-Hsiu
    Huang, Shuo
    Poblete, Alexander
    Cho, Steve
    Britton, William
    Chen, Jing
    Smith, Lois E. H.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [9] Preclinical Evaluation of FGF21 or Liraglutide in Combination with a Long-Acting DACRA in DIO Mice
    Sun, Gao
    Zhou, Su
    John, Linu
    Raun, Kirsten
    OBESITY, 2021, 29 : 144 - 144
  • [10] Development of a Novel Long-Acting Antidiabetic FGF21 Mimetic by Targeted Conjugation to a Scaffold Antibody
    Huang, Jie
    Ishino, Tetsuya
    Chen, Gang
    Rolzin, Paul
    Osothprarop, Trina F.
    Retting, Kelsey
    Li, Lingna
    Jin, Ping
    Matin, Marla J.
    Huyghe, Bernard
    Talukdar, Saswata
    Bradshaw, Curt W.
    Palanki, Moorthy
    Violand, Bernard N.
    Woodnutt, Gary
    Lappe, Rodney W.
    Ogilvie, Kathleen
    Levin, Nancy
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2013, 346 (02): : 270 - 280
12345